LONDON (Alliance News) - Hikma Pharmaceuticals PLC on Friday said a US subsidiary has launched its version of Dexrazoxane for Injection, a generic equivalent for heart disease treatment Zinecardi.
Zinecardi is owned by Pharmacia and Upjohn Co LLC.
West-Ward Pharmaceuticals Corp has launched the treatment in 250 milligram and 500 milligram doses via injection.
Dexrazoxane, the FTSE 250-listed firm said, is a treatment reducing the incidence and severity of heart problems in women received the drug doxorubicin for breast cancer.
According to market research firm IQVIA, Hikma added, sales in the US of Dexrazoxane for Injection in the 12 months to February were around USD15.0 million.
Hikma's Chief Executive of Injectables Riad Mechlaoui said: "We are very pleased to be adding dexrazoxane for injection to our oncology portfolio.
"By launching dexrazoxane, we hope to reduce the shortage of this product in the US market."
Shares were up 3.1% on Friday morning at 1,220.50 pence each.
Hikma Pharmaceuticals (HIK)